TapImmune is a biotech company focused on innovative therapeutics for oncology and infectious disease whose remarkable TAP (transporters associated with antigen processing) technology platform has broad applications for developing therapeutic and preventative vaccines. The revolutionary AdhTAP therapeutic vaccine based on the TAP technology is able to help the immune system correctly identify and attack cancer cells.
But the TAP molecule can also function as a prophylactic vaccine and adjuvant (enhancer) for targeted vaccines in a variety of infectious diseases because it acts by restoring marker (antigen) expression in the host’s own cells, priming the immune system and allowing it to do its job properly, which is a major leap forward for therapeutic cancer vaccines.
The incredible future of the market for TAP in cancer vaccines places the Company in a prime position to generate impressive revenues through a superior product which, unlike existing chemotherapy, surgery or radiation, can address all cancer cells and do so in a way that is of much lower impact to the patient.
Let us hear your thoughts: TapImmune, Inc. Message Board